ALDX
ALDX
Positions held
Your positionsALDX isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | — | Enterprise value | — | Trailing P/E | — | Forward P/E | — |
| PEG | — | Price / book | — | Beta | — | Dividend yield | — |
| Revenue growth | — | Earnings growth | — | Gross margin | — | Operating margin | — |
| Profit margin | — | ROE | — | ROA | — | Debt / equity | — |
| Current ratio | — | Free cash flow | — | Analyst recommendation | — | Mean target | — |
| 52w high | — | 52w low | — |
Quarterly
No data yet.
Yearly (6y)
No data yet.
Headline risk — review
• [CRITICAL · regulatory] Aldeyra Therapeutics Plans Formal FDA Dispute Resolution Request for Reproxalap After Third Complete Response Letter
News
2026-10-08 · Here's Why You Should Add LPCN Stock to Your Portfolio Now
2026-10-08 · Ultragenyx to Sell Rare Pediatric Disease PRV for $210M to Boost Cash
2026-10-07 · ETON Stock Surges 108% in Six Months: Here's What You Need to Know
2026-10-06 · AGIO Stock Sinks 29% in Three Months: Here's What You Need to Know
2026-10-06 · PCRX Expands Exparel Commercial Reach in Europe Through Molteni Deal
2026-10-05 · Ultragenyx's Gene Therapy for Sanfilippo Syndrome Wins EMA Validation
2026-10-05 · Novo's Denecimig BLA Review Delayed by FDA Facility Remediation Work
2026-10-01 · Novo's Wegovy Pill Shows Weight Loss After Switching From Injections
2026-09-29 · Aldeyra to Appeal FDA Rejection of Reproxalap for Dry Eye Disease
2026-09-29 · Aldeyra Therapeutics Plans Formal FDA Dispute Resolution Request for Reproxalap After Third Complete Response Letter
2026-09-29 · Merck Inks $2.1B Deal With Chinese Biotech to Expand Oncology Pipeline
2026-09-29 · Acadia's Daybue Patent Allowance Extends U.S. Protection to March 2041
Price (daily)
Full chart · RSI · MACD · patterns